Supernus and Indivior report sales growth ahead of their expected merger closing
Supernus ($SUPN) reported third-quarter 2026 revenue of $226.8 million, up 18%, with Qelbree sales increasing 12% to $90.8 million and Onapgo contributing $17.1 million. Separately, merger partner Indivior ($INDV) posted revenue of $356 million, up 13%. Its Sublocade treatment generated $267 million, increasing 22%, supported by US dispensing growth as well as favorable pricing, mix and gross-to-net adjustments. Indivior’s net income rose to $137 million from $42 million, and adjusted EBITDA inc
0